FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response

Today, the FDA announced another step in their effort to harness diverse streams of data to understand and respond to COVID-19. The U.S. Food and Drug Administration has entered into an agreement with Aetion to collaborate on advanced analytical techniques to answer urgent coronavirus disease (COVID-19) research questions.

The FDA and Aetion aim to answer questions about the use of diagnostics and medications in the pandemic, and risk factors for COVID-19-related complications in different patient populations. They believe that this work has the potential to contribute to the scientific evaluation of potential diagnostics and interventions for COVID-19.

The FDA continues to work around the clock to respond to the COVID-19 pandemic. As part of this effort, the FDA recognizes the potential for diverse, real-world data sources such as electronic health records, insurance claims, patient registries and lab results to further inform their science-based, all-of-America response to this unprecedented public health emergency.

In recent years, the agency has taken steps to leverage modern, rigorous analyses of real-world data—such as data from the health care setting—to inform our work. The COVID-19 pandemic has brought an urgency to these efforts and the FDA has worked quickly to advance collaborations with public and private partners to collect and analyze a variety of real-world data sources. Evaluation of real-world data has the potential to provide a wealth of rapid, actionable information to better understand disease symptoms, describe and measure immunity and understand available medical product supplies to help mitigate potential shortages. These data can also inform ongoing work to evaluate potential therapies, vaccines or diagnostics for COVID-19.

The FDA is applying data from diverse sources to inform its response to COVID-19, including sources that were already available to the agency, such as Sentinel. The urgency of addressing the COVID-19 pandemic has demanded that they work to identify, access and analyze new datasets to widen the breadth of the information available. This work is being done in collaboration with partners in the U.S. government, academia and industry.

For example, the FDA is a proud participant in the COVID-19 Evidence Accelerator, organized by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research. The COVID-19 Evidence Accelerator brings together leading experts in health data aggregation and analytics in a unified, collaborative effort to share insights, compare results and answer key questions to inform the collective COVID-19 response. By developing common data elements and questions, the Evidence Accelerator creates a strong foundation for rapid collection and rigorous analysis of real-world data to answer urgent questions about COVID-19.

The FDA is regularly engaging with stakeholders — medical product industry leaders and scientists, academic researchers, technology companies, state and local governments and patient groups — to hear from them on how they can come together as a public/private health community to harness the power of data during this emergency. We’re optimistic that these efforts will assist in, among other things, the FDA’s work to facilitate medical countermeasures to diagnose, treat and prevent COVID-19, mitigate any potential shortages in the medical product and food supply chains, ensure the safety and quality of FDA-regulated products and provide the industries they regulate the tools and flexibility to do the same.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy